Moderna Surges 14% Amid FDA Vaccine Endorsement and Strong Q1 Performance
Moderna (NASDAQ:MRNA) shares rose 14% on June 26, driven by an FDA endorsement of its flu vaccine candidate mFlusiva and a strong first-quarter revenue beat. The stock outperformed peers Merck (NYSE:MRK) and Pfizer (NYSE:PFE), which gained around 2%. Despite the surge, Wall Street's price target remains below current levels.
Topics: FDA approval Moderna pipeline developments vaccine stocks